Placebo controlled study of Haloperidol in Schizophrenia.

Main Article Content

Shams-ul-Arfeen Khan
Bhurgri G.R
Farooq Baig

Abstract

Objective: The present study aimed to compare the efficacy and safety of haloperidol with placebo in firstepisode schizophrenia.
Place and Time: The sample (n=64) was selected from the outpatient department of the Sir Cows Jee Jehangir
Institute of Psychiatry Hyderabad (CJIP). The selected patients were admitted and randomly grouped (32) to receive haloperidol and placebo (multivitamin). This study was single blinded. Duration of study was three months
from Jan 2011 to March 2011.
Results: Improvements in PANSS, PBRS score from baseline, by haloperidol week-1 2.6 ± 1.63, .67, by placebo
1 results showed < 0.05 siginificant. In week-2 3.14 ± 1.95, .74, by placebo 1.50 ± .71, 50, results showed <0.05
significant. In week-3 2.6 ± 1.63, .67 results showed <0.05 significant. In week-4 3.00 ± 1.58, .71. by placebo 1
results showed <0.05 significant. In week-5 2.50 ± 1.29, .65, by placebo 1 results showed >0.05 insignificant. In
week-6 3.00 ± 1.58,.71, by placebo1 results showed >0.05 insignificant.
Conclusion: In patients with schizophrenia, haloperidol is better than placebo for disease improvement but increases the rates of parkinsonism, akathisia, and acute dystonias substantially.
Key Words: Psychosis, Schizophrenia, Haloperidol, Placebo, Akathesia, Dystonia.

Downloads

Download data is not yet available.

Article Details

How to Cite
Shams-ul-Arfeen Khan, Bhurgri G.R, & Farooq Baig. (2013). Placebo controlled study of Haloperidol in Schizophrenia. JMMC, 4(1), 7-10. https://doi.org/10.62118/jmmc.v4i1.414
Section
Original Article